Dow Up0.51% Nasdaq Up0.24%

Bio-Techne Corp. (TECH)

90.26 Up 0.50(0.56%) Nov 21, 4:00PM EST
ProfileGet Profile for:
Bio-Techne Corp.
614 McKinley Place North East
Minneapolis, MN 55413
United States - Map
Phone: 612-379-8854

Index Membership:N/A
Full Time Employees:967

Business Summary 

Bio-Techne Corporation develops, manufactures, and sells biotechnology products and clinical diagnostic controls worldwide. It operates in two segments, Biotechnology and Clinical Controls. The Biotechnology segment provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits used by researchers to quantify the level of a specific protein in biological fluids, such as serum, plasma, or urine; and clinical diagnostic immunoassay kits consisting of erythropoietin, transferrin receptor, and Beta2-microglobulin immunoassays for use as in vitro diagnostic devices. This segment also offers flow cytometry products, such as fluorochrome labeled antibodies and kits for use in determining the immuno-phenotypic properties of cells from various tissues; and natural and synthetic chemical compounds for use by investigators as agonists, antagonists, and/or inhibitors of various biological functions. The Clinical Controls segment provides a range of hematology controls and calibrators for impedance and laser type cell counters; and hematology control products for use as proficiency testing tools by laboratory certifying authorities. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Bio-Techne Corp.

Corporate Governance 
Bio-Techne Corp.’s ISS Governance QuickScore as of Nov 1, 2014 is 4. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 1; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Charles R. Kummeth , 54
Chief Exec. Officer, Pres and Director
Dr. Roger C. Lucas Ph.D., 71
Vice Chairman, Sr. Scientific Advisor, Member of Nominations & Governance Committee and Member of Scientific Subcommittee
Mr. James T. Hippel , 43
Chief Financial Officer and VP of Fin.
Dr. J. Fernando Bazan Ph.D., 54
Chief Technical Officer
Mr. Marcel Veronneau , 60
Sr. VP of Clinical Controls
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders